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Abstract
Background: Both C reactive protein (CRP) and procalcitonin (PCT) are well known acute phase
reactant proteins. CRP was reported to increase in metabolic syndrome and type-2 diabetes.
Similarly altered level of serum PCT was found in chronic liver diseases and cirrhosis. The liver is
considered the main source of CRP and a source of PCT, however, the serum PCT and CRP levels
in non-alcoholic fatty liver disease (NAFLD) were not compared previously. Therefore we aimed
to study the diagnostic and discriminative role of serum PCT and CRP in NAFLD.
Methods: Fifty NAFLD cases and 50 healthy controls were included to the study. Liver function
tests were measured, body mass index was calculated, and insulin resistance was determined by
using a homeostasis model assessment (HOMA-IR). Ultrasound evaluation was performed for each
subject. Serum CRP was measured with nephalometric method. Serum PCT was measured with
Kryptor based system.
Results: Serum PCT levels were similar in steatohepatitis (n 20) and simple steatosis (n 27)
patients, and were not different than the control group (0.06 ± 0.01, 0.04 ± 0.01 versus 0.06 ± 0.01
ng/ml respectively). Serum CRP levels were significantly higher in simple steatosis, and
steatohepatitis groups compared to healthy controls (7.5 ± 1.6 and 5.2 ± 2.5 versus 2.9 ± 0.5 mg/
dl respectively p < 0.01). CRP could not differentiate steatohepatitis from simple steatosis. Beside,
three patients with focal fatty liver disease had normal serum CRP levels.
Conclusion:  Serum PCT was within normal ranges in patients with simple steatosis or
steatohepatitis and has no diagnostic value. Serum CRP level was increased in NAFLD compared
to controls. CRP can be used as an additional marker for diagnosis of NAFLD but it has no value
in discrimination of steatohepatitis from simple steatosis.
Background
Non alcoholic fatty liver disease (NAFLD) is increasing
health problem especially in western countries [1,2]. It is
usually associated with co-morbidities including hyperli-
pidemia, diabetes or metabolic syndrome [3]. Although
initially it is considered as benign disorder, now it is
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accepted that the spectrum of the disease ranges from sim-
ple steatosis to steatohepatitis, even to cirrhosis [4]. There
are no noninvasive serum markers suggesting or reflecting
the disease stage.
Both CRP and PCT are acute phase reactant proteins [5].
They are easy to reach, commonly used, reliable, inexpen-
sive serum markers and extensively used for diagnosis and
follow up of several morbidities [5,6]. CRP is synthesized
mainly in the liver. The serum CRP level was reported to
increase in metabolic syndrome and diabetes [7]. CRP has
also been suggested as a predictor of cardiovascular events
in patients with metabolic syndrome [7,8]. PCT, a 116-
amino acid pro-hormone of calcitonin, is normally syn-
thesized in C cells of thyroid gland. However even thy-
roidectomised subjects have maintained PCT response
during acute inflammation suggesting possible other
sources of PCT production including liver and inflamma-
tory cells. PCT was found to be increased in bacterial
infections and sepsis [9]. Similarly altered level of serum
PCT has been reported in chronic liver diseases and cir-
rhosis. On the other hand serum PCT levels are not ele-
vated by viral or autoimmune diseases of the liver [10].
The liver is considered the main source of CRP and a
source of PCT; however, the serum PCT levels in NAFLD
were not investigated previously. Therefore we aimed to
study the diagnostic and discriminative role of serum PCT
and CRP in NAFLD.
Methods
Between January 2005 and 2006 all patients admitted to
Hepatology outpatient unit with elevated liver function
tests, no alcohol history, no drug usage, with negative
viral hepatitis and autoimmune serology were further
evaluated for NAFLD. Patients with suspected toxic liver
disease, cholestatic liver disorders, obstructive jaundice,
previously diagnosed Wilson diseases, hemochomatosis,
gastrointestinal bypass surgery, systemic disorders and
infections were excluded from the study. None of the
patients was using statin, corticosteroids or any other
medication that known to affect serum CRP levels. Out of
total 258 patients evaluated 50 patients were included to
the study.
Patients were subjected to general physical examination
and routine laboratory investigations. All subjects had
normal white blood cell count, urine analysis. Physical
examination revealed no sign of infection. Body mass
index (BMI) was calculated, ultrasound evaluation was
performed for each subject. Liver biopsy was performed
when indicated. Histopathological evaluations were per-
formed with an experienced pathologist according to clas-
sification suggested by Brunt et al. Briefly, steatosis was
classified as S0, no steatosis; S1, < 30% of the hepatocytes
in the biopsy with macrovesicular steatosis; S2, 30–60%
of the hepatocytes with macrovesicular steatosis; and S3,
> 60% of the hepatocytes with macrovesicular steatosis.
Nonalcoholic steatohepatitis was diagnosed when the
presence of steatosis with hepatocellular ballooning and/
or necrosis was associated with neutrophil polymorpho-
nuclear cell infiltration. A total of 50 consecutive patients
(33 males and 17 females, age 54.7 ± 14.8 years) with liver
biopsy proven NAFLD were included to the study. Results
were compared with healthy volunteers (n 50, mean age
45.1 ± 4.3). Ultasonoghraphic evaluation of control sub-
jects confirmed that there was no NAFLD. Liver function
tests were normal in controls.
Blood samples were withdrawn at the same day with
definitive diagnosis. Fasting blood samples were obtained
and used for determination of glycemia, insulinemia, cho-
lesterol, HDL- and LDL-cholesterol, and liver function
tests. Insulin resistance was determined by using a home-
ostasis model assessment of insulin resistance (HOMA-
IR) [11]. Serum CRP was measured with nephalometric
method. PCT was measured in plasma samples with Kryp-
tor based system as suggested by the company.
(B.R.A.H.M.S.-Diagnostica, Berlin, Germany). Lowest
detection limit was 0.01 ng/ml. Values of PCT levels > 0.5
Table 1: General characteristic of NAFLD patients.
Steatohepatitis (n 20) Diffuse Steatosis(n 27) Focal Fatty Liver (n 3) Controls (n 50)
Age(years) 54.1 ± 13.2 45.1 ± 6.3 56.1 ± 3.1 43.8 ± 17.5
BMI (kg\m2) 30.6 ± 1.4 34.7 ± 4.5 26.7 ± 0.5 28.1 ± 5.3*
ALT (U\l) 68.0 ± 12.7 69.6 ± 16.2 42.0 ± 15.0 28.4 ± 1.1*
AST (U\l) 54.1 ± 13.2 45.2 ± 6.3 68.0 ± 7.0 27.3 ± 1.2*
GGT 62.8 ± 9.9 53.2 ± 5.9 48.0 ± 8.1 49.3 ± 8.5
Cholesterol (mg\dl) 203.8 ± 15.2 174.0 ± 13.3 167.0 ± 10.2 171 ± 10.1
Triglyceride (mg\dl) 214.0 ± 47.4 134.8 ± 15.9 73.0 ± 15.2 90 ± 10.5
HOMA-IR 6.2 ± 1.4 4.9 ± 0.9 1.5 ± 0.8 1.4 ± 0.8*
USG Steatosis Grade 2.04 ± 0.01 1.87 ± 0.22 0 0
*BMI of healthy controls was lower than steatohepatitis and steatosis patients. Liver function tests, HOMA-IR value were significantly higher in 
NAFLD groups compared to controls (p < 0.01)BMC Gastroenterology 2009, 9:16 http://www.biomedcentral.com/1471-230X/9/16
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ng/ml were considered as abnormal, as proposed by the
manufacturer.
Study was performed with the approval of Ege University
local ethics committee and carried out in compliance with
the Helsinki Declaration. Written informed consent was
given by all subjects. Results were given as mean ± SEM.
SPSS statistical package (SPSS software, PC version 11.5;
SPSS, Chicago IL) was used for statistical analyses. Statis-
tical analysis was based on paired Student's t-test and the
nonparametric Kruskall-Wallis test. ROC analysis was
conducted to calculate sensitivity and specificity of the
markers. P < 0.05 was considered as significant.
Results
A total of 50 consecutive patients with liver biopsy proven
NAFLD were included to the study. Results were com-
pared with healthy volunteers (n:50, mean age 45.1 ±
4.3). Age and gender distribution was similar between
NAFLD group and healthy controls. Patient's and con-
trol's characteristics were given in Table 1.
Liver biopsy proved the diagnosis of steatohepatitis in 20,
diffuse steatosis in 27 and focal fatty infiltration in 3 sub-
jects (Figure 1). Patients with steatohepatitis or steatosis
had high HOMA-IR values demonstrating the presence of
insulin resistance. Serum AST and ALT concentrations,
BMI, and HOMA-IR values were significantly higher in
NAFLD group compared to controls (p < 0.01) (Table 1).
Serum PCT levels were within normal ranges in both
NAFLD and control group. There was no significant differ-
ence between the steatohepatitis, steatosis and control
group in PCT levels (0.06 ± 0.01 and 0.04 ± 0.01 versus
0.06 ± 0.01 ng/ml respectively). Serum CRP levels were
significantly increased in patients with steatohepatitis and
steatosis compared to controls. (5.2 ± 2,5 and 7.5 ± 1.6
versus 2.9 ± 0.5 mg/dl respectively p < 0.01). However
there was no significant difference between steatohepatitis
and steatosis patients in serum CRP levels. Three patients
with focal fatty liver disease had normal serum CRP and
PCT levels (Table 2)
When patients were divided into two groups according to
presence of insulin resistance, insulin resistance did not
affect the CRP and PCT levels in NAFLD patients (Table
3). PCT was not correlated with liver function tests, BMI
or presence of insulin resistance. ROC curve analysis rev-
eled that serum CRP levels above 3 has 73% sensitivity
and 68% specificity for NAFLD.
Discussion
Diagnostic and prognostic value of serum PCT level in
liver disorders has been evaluated in some studies with
controversial results [12]. In patients with decompensated
liver cirrhosis high PCT level was sensitive and specific
tool for the initial diagnosis of bacterial infection [13]. On
the other hand acute alcoholic hepatitis as well as acute
viral hepatitis on cirrhotic background without proved
bacterial infection induce mild elevation of serum PCT
levels [14,15]. Our study revealed that serum PCT level
was within normal ranges in both steatohepatitis and
steatosis patients for the first time in the literature. This
finding suggests that PCT is a specific marker for infection
and does not necessarily increase in fatty infiltration or
inflammation located in the liver. Although we did not
Table 2: Serum PCT and CRP levels in study groups.
CONTROLS NAFLD P value
(n 50) Focal Fatty liver (n3) Steatohepatitis (n20) Steatosis (n27)
PCT 0.06 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.04 ± 0.01 ns
CRP 2.90 ± 0.50 1.70 ± 0.70 5.20 ± 2.50* 7.50 ± 1.60* < 0.01
Serum CRP levels were significantly higher in simple steatosis and steatohepatitis groups compared to healthy controls (*p < 0.01). There were no 
significant differences between groups in serum PCT levels.
Portal inflammation is a diagnostic finding in NASH Figure 1
Portal inflammation is a diagnostic finding in NASH. 
Histopathologic section was obtained from one of patients 
with steatohepatitis. [HE stain, ×40]BMC Gastroenterology 2009, 9:16 http://www.biomedcentral.com/1471-230X/9/16
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evaluate the expression pattern of PCT we might speculate
that liver is not the main source of PCT production. PCT
was not correlated with liver function tests, BMI or pres-
ence of insulin resistance either.
We also evaluated the clinical usefulness of CRP in the
diagnosis of NAFLD. There were limited number of stud-
ies implying that serum CRP was elevated in NAFLD [16-
18]. CRP has short life around 18 hours and the elevation
of serum CRP usually reflects its synthesis in response to a
pathological process [19]. CRP is therefore considered as
a useful nonspecific biochemical marker of chronic
inflammation [19]. Our study confirmed that the increase
in circulating CRP levels could be by itself a marker of the
presence of NAFLD. The C reactive protein response how-
ever alone has no diagnostic specificity. Due to its low
specificity, C reactive protein values can really only be
interpreted when all other clinical and laboratory infor-
mation is available. We therefore suggest that serial meas-
urements of CRP can be helpful in clinical management
and follow up of NAFLD patients.
In clinical trials CRP elevation was related to metabolic
syndrome and its components. Although the liver is main
source of the CRP production, fat tissue, especially visceral
fat significantly contributes to CRP production [20]. But
there is no evidence about the synthesis of PCT by adipose
tissue. It is also well known that CRP concentration was
elevated in severely obese patients but this elevation was
moderate and not related to metabolic syndrome, diabe-
tes, and more importantly to steatohepatitis [20]. In con-
cordance with that our study failed to show any
association between the presence of insulin resistance,
and serum CRP or PCT levels. Since both steatohepatitis
and steatosis group was obese in our study, similarly ele-
vated CRP probably was related to adiposity.
Another proposed mechanism for CRP response in
NAFLD is the elevation in acute phase cytokines. IL-6 for
example, is a potent stimulator for CRP synthesis. Hauke-
land et al. reported that both patients with simple steato-
sis and steatohepatitis had significantly raised serum
levels of IL-6 compared with healthy controls [16].
Although we did not measure the serum level of inflam-
matory cytokines, this might explain the equally elevated
serum CRP levels in both steatohepatitis and steatosis
groups in our study. Unfortunately, this common patho-
genesis decreases the discriminative role of CRP for stea-
tohepatitis. Acute effects of those cytokines on PCT levels
were already demonstrated in experimental studies, but
this affect is obviously less then expected in NAFLD [21]
Conclusion
Serum PCT was within normal ranges in patients with
simple steatosis or steatohepatitis and has no diagnostic
value in NAFLD. CRP can be used as an additional marker
for diagnosis of NAFLD but it has no value in discrimina-
tion of steatohepatitis from simple steatosis. Obesity but
not the insulin resistance is determining factor for the
serum CRP levels. Serial measurements of CRP levels in
obese patients might increase its diagnostic value in
NAFLD and should be evaluated in further studies.
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